{"id":"https://openalex.org/W2160318185","doi":"https://doi.org/10.1016/j.molonc.2009.01.002","title":"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530","display_name":"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530","publication_year":2009,"publication_date":"2009-01-28","ids":{"openalex":"https://openalex.org/W2160318185","doi":"https://doi.org/10.1016/j.molonc.2009.01.002","mag":"2160318185","pmid":"https://pubmed.ncbi.nlm.nih.gov/19393585","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5527863"},"language":"en","primary_location":{"id":"doi:10.1016/j.molonc.2009.01.002","doi":"https://doi.org/10.1016/j.molonc.2009.01.002","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.molonc.2009.01.002","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.molonc.2009.01.002","source":{"id":"https://openalex.org/S80282989","display_name":"Molecular Oncology","issn_l":"1574-7891","issn":["1574-7891","1878-0261"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.molonc.2009.01.002","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031871834","display_name":"Tim P. Green","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Tim P. Green","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK. timgreen350@googlemail.com","Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK. timgreen350@googlemail.com","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108538760","display_name":"Mike Fennell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mike Fennell","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024833406","display_name":"Robin D. Whittaker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robin Whittaker","raw_affiliation_strings":["Clinical Development, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054135360","display_name":"Jon Curwen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jon Curwen","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111628033","display_name":"Vivien N. Jacobs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Vivien Jacobs","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049466023","display_name":"J M Allen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jack Allen","raw_affiliation_strings":["Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111854142","display_name":"Armelle Logi\u00e9","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Armelle Logie","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000334337","display_name":"Judith A. Hargreaves","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Judith Hargreaves","raw_affiliation_strings":["Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology and DMPK, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085929097","display_name":"D. Mark Hickinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"D. Mark Hickinson","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044215747","display_name":"Robert W. Wilkinson","orcid":"https://orcid.org/0000-0001-8180-2643","observed_orcids":["https://orcid.org/0000-0001-8180-2643"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Robert W. Wilkinson","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111869571","display_name":"Paul Elvin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul Elvin","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110148414","display_name":"Brigitte Boyer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Brigitte Boyer","raw_affiliation_strings":["Inserm U784, 46 Rue d'Ulm, 75230 Paris, Cedex 05, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inserm U784, 46 Rue d'Ulm, 75230 Paris, Cedex 05, France","institution_ids":["https://openalex.org/I154526488"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066808283","display_name":"Neil O. Carragher","orcid":"https://orcid.org/0000-0001-5541-9747","observed_orcids":["https://orcid.org/0000-0001-5541-9747"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Neil Carragher","raw_affiliation_strings":["Advanced Science and Technology Laboratory, AstraZeneca R&D, Charnwood, Bakewell Road, Loughborough, LE11 5RH, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Advanced Science and Technology Laboratory, AstraZeneca R&D, Charnwood, Bakewell Road, Loughborough, LE11 5RH, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063034949","display_name":"Patrick A. Pl\u00e9","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Patrick A. Pl\u00e9","raw_affiliation_strings":["Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071778044","display_name":"Alun Bermingham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"Alun Bermingham","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","Present address: Molecular Targets Development Program, National Cancer Institute, Building 562, Fort Detrick, Frederick, MD 21702-1201, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"Present address: Molecular Targets Development Program, National Cancer Institute, Building 562, Fort Detrick, Frederick, MD 21702-1201, USA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000222199","display_name":"Geoffrey A. Holdgate","orcid":"https://orcid.org/0000-0002-1863-1084","observed_orcids":["https://orcid.org/0000-0002-1863-1084"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Geoffrey A. Holdgate","raw_affiliation_strings":["Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108797297","display_name":"Walter H.J. Ward","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Walter H.J. Ward","raw_affiliation_strings":["Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Enabling Capabilities & Sciences, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027147959","display_name":"Laurent Fran\u00e7ois Hennequin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210110908","display_name":"AstraZeneca (France)","ror":"https://ror.org/016qv5070","country_code":"FR","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210110908"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Laurent F. Hennequin","raw_affiliation_strings":["Cancer and Infection Research Area Reims, AstraZeneca, Centre de Recherches, Z.I. La Pompelle B.P. 1050, 51689 Reims Cedex 2, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area Reims, AstraZeneca, Centre de Recherches, Z.I. La Pompelle B.P. 1050, 51689 Reims Cedex 2, France","institution_ids":["https://openalex.org/I4210110908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000275517","display_name":"Barry R. Davies","orcid":"https://orcid.org/0000-0002-5414-9113","observed_orcids":["https://orcid.org/0000-0002-5414-9113"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Barry R. Davies","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083456433","display_name":"Gerard F. Costello","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gerard F. Costello","raw_affiliation_strings":["Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer and Infection Research Area, AstraZeneca, Alderley Park, Macclesfield Cheshire, SK10 4TG, UK","institution_ids":["https://openalex.org/I105036370"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5031871834"],"corresponding_institution_ids":["https://openalex.org/I105036370"],"apc_list":{"value":4300,"currency":"USD","value_usd":4300},"apc_paid":null,"fwci":6.3692,"has_fulltext":true,"cited_by_count":239,"citation_normalized_percentile":{"value":0.96988468,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"3","issue":"3","first_page":"248","last_page":"261"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.7602999806404114,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.7602999806404114,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.08839999884366989,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":0.028300000354647636,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/azd0530","display_name":"AZD0530","score":1.0},{"id":"https://openalex.org/keywords/src-inhibitors","display_name":"Src kinase inhibitor","score":0.8500000238418579},{"id":"https://openalex.org/keywords/bladder-cancer","display_name":"bladder cancer","score":0.8980000019073486},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.7639999985694885},{"id":"https://openalex.org/keywords/cell-migration-inhibition","display_name":"cell migration inhibition","score":0.7089999914169312},{"id":"https://openalex.org/keywords/tumor-invasion","display_name":"tumor invasion","score":0.7739999890327454},{"id":"https://openalex.org/keywords/cell-cell-adhesion","display_name":"cell-cell adhesion","score":0.8059999942779541},{"id":"https://openalex.org/keywords/paxillin","display_name":"paxillin","score":0.7799999713897705},{"id":"https://openalex.org/keywords/focal-adhesion-kinase","display_name":"focal adhesion kinase","score":0.9869999885559082},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7260000109672546},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.8209999799728394}],"concepts":[{"id":"https://openalex.org/C116581196","wikidata":"https://www.wikidata.org/wiki/Q14906591","display_name":"Paxillin","level":4,"score":0.7274113297462463},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5978465676307678},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5414483547210693},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.5317769050598145},{"id":"https://openalex.org/C108636557","wikidata":"https://www.wikidata.org/wiki/Q21109354","display_name":"Proto-oncogene tyrosine-protein kinase Src","level":3,"score":0.502730131149292},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4741617739200592},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.41664689779281616},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.40858137607574463},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38764458894729614},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.36024901270866394},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.35933277010917664},{"id":"https://openalex.org/C85789140","wikidata":"https://www.wikidata.org/wiki/Q187640","display_name":"Cell adhesion","level":3,"score":0.2944643795490265},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27578333020210266},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17296165227890015},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D001749","descriptor_name":"Urinary Bladder Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002465","descriptor_name":"Cell Movement","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009361","descriptor_name":"Neoplasm Invasiveness","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009363","descriptor_name":"Neoplasm Proteins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D009363","descriptor_name":"Neoplasm Proteins","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009368","descriptor_name":"Neoplasm Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010766","descriptor_name":"Phosphorylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011923","descriptor_name":"Rats, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014183","descriptor_name":"Transplantation, Heterologous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019061","descriptor_name":"src-Family Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D019061","descriptor_name":"src-Family Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D041681","descriptor_name":"NIH 3T3 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051417","descriptor_name":"Focal Adhesion Kinase 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051419","descriptor_name":"Paxillin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D052117","descriptor_name":"Benzodioxoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1016/j.molonc.2009.01.002","doi":"https://doi.org/10.1016/j.molonc.2009.01.002","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.molonc.2009.01.002","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.molonc.2009.01.002","source":{"id":"https://openalex.org/S80282989","display_name":"Molecular Oncology","issn_l":"1574-7891","issn":["1574-7891","1878-0261"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Oncology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5527863","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5527863","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Mol Oncol","raw_type":"Text"},{"id":"pmid:19393585","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19393585","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.ed.ac.uk:openaire/61984036-78d3-4781-8127-10bbe0df107f","doi":null,"is_oa":true,"landing_page_url":"https://www.research.ed.ac.uk/en/publications/61984036-78d3-4781-8127-10bbe0df107f","pdf_url":null,"source":{"id":"https://openalex.org/S4306400321","display_name":"Edinburgh Research Explorer (University of Edinburgh)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I98677209","host_organization_name":"University of Edinburgh","host_organization_lineage":["https://openalex.org/I98677209"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Green, T P, Fennell, M, Whittaker, R, Curwen, J, Jacobs, V, Allen, J, Logie, A, Hargreaves, J, Hickinson, D M, Wilkinson, R W, Elvin, P, Boyer, B, Carragher, N, Pl\u00e9, P A, Bermingham, A, Holdgate, G A, Ward, W H J, Hennequin, L F, Davies, B R & Costello, G F 2009, 'Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530', Molecular Oncology, vol. 3, no. 3, pp. 248-261. https://doi.org/10.1016/j.molonc.2009.01.002","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1016/j.molonc.2009.01.002","doi":"https://doi.org/10.1016/j.molonc.2009.01.002","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.molonc.2009.01.002","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1016/j.molonc.2009.01.002","source":{"id":"https://openalex.org/S80282989","display_name":"Molecular Oncology","issn_l":"1574-7891","issn":["1574-7891","1878-0261"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2160318185.pdf","grobid_xml":"https://content.openalex.org/works/W2160318185.grobid-xml"},"referenced_works_count":54,"referenced_works":["https://openalex.org/W130020229","https://openalex.org/W1462994058","https://openalex.org/W1589166971","https://openalex.org/W1594706458","https://openalex.org/W1679250118","https://openalex.org/W1944985511","https://openalex.org/W1967702420","https://openalex.org/W1980488526","https://openalex.org/W1982244057","https://openalex.org/W1992945955","https://openalex.org/W1992964109","https://openalex.org/W1996537616","https://openalex.org/W2003973314","https://openalex.org/W2008952509","https://openalex.org/W2010455039","https://openalex.org/W2011017763","https://openalex.org/W2020537787","https://openalex.org/W2024161072","https://openalex.org/W2024262880","https://openalex.org/W2026991540","https://openalex.org/W2028508216","https://openalex.org/W2030565228","https://openalex.org/W2032103583","https://openalex.org/W2032775411","https://openalex.org/W2034919226","https://openalex.org/W2037327502","https://openalex.org/W2038900319","https://openalex.org/W2040412126","https://openalex.org/W2045792003","https://openalex.org/W2046163031","https://openalex.org/W2059552745","https://openalex.org/W2069667670","https://openalex.org/W2075954169","https://openalex.org/W2086641174","https://openalex.org/W2097373408","https://openalex.org/W2101257013","https://openalex.org/W2101443436","https://openalex.org/W2107815302","https://openalex.org/W2127085870","https://openalex.org/W2128701004","https://openalex.org/W2129926378","https://openalex.org/W2138067522","https://openalex.org/W2138072853","https://openalex.org/W2143974518","https://openalex.org/W2153850465","https://openalex.org/W2157342751","https://openalex.org/W2164193456","https://openalex.org/W2166477912","https://openalex.org/W2174216670","https://openalex.org/W2268605619","https://openalex.org/W2325228859","https://openalex.org/W2399195461","https://openalex.org/W2746073827","https://openalex.org/W2968310212"],"related_works":["https://openalex.org/W1835497562","https://openalex.org/W2268605619","https://openalex.org/W2041809276","https://openalex.org/W2968310212","https://openalex.org/W7019812135","https://openalex.org/W2589674573","https://openalex.org/W1529540522","https://openalex.org/W7021078175","https://openalex.org/W2954236693","https://openalex.org/W4397013188"],"abstract_inverted_index":{"AZD0530,":[0],"an":[1],"orally":[2],"available":[3],"Src":[4,53],"inhibitor,":[5],"demonstrated":[6],"potent":[7],"antimigratory":[8],"and":[9,14,46,56,61,82],"anti-invasive":[10,92],"effects":[11],"in":[12,17,28,41,49,58,68,73,101,109],"vitro,":[13],"inhibited":[15,38,48],"metastasis":[16],"a":[18,90,102],"murine":[19],"model":[20],"of":[21,26,52,66,79,84,104],"bladder":[22,70],"cancer.":[23],"Antiproliferative":[24],"activity":[25,65],"AZD0530":[27,37,67,95,106],"vitro":[29,74],"varied":[30],"between":[31],"cell":[32,80],"lines":[33],"(IC(50)":[34],"0.2":[35],"->10\u03bcM).":[36],"tumor":[39,99],"growth":[40],"4/10":[42],"xenograft":[43],"models":[44],"tested":[45],"dynamically":[47],"vivo":[50],"phosphorylation":[51],"substrates":[54],"paxillin":[55],"FAK":[57],"both":[59],"growth-inhibition-resistant":[60],"-sensitive":[62],"xenografts.":[63],"The":[64],"NBT-II":[69],"cancer":[71],"cells":[72],"was":[75],"consistent":[76],"with":[77],"inhibition":[78],"migration":[81],"stabilization":[83],"cell-cell":[85],"adhesion.":[86],"These":[87],"data":[88],"suggest":[89],"dominant":[91],"pharmacology":[93],"for":[94],"that":[96],"may":[97],"limit":[98],"progression":[100],"range":[103],"cancers.":[105],"is":[107],"currently":[108],"Phase":[110],"II":[111],"clinical":[112],"trials.":[113]},"counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":23},{"year":2021,"cited_by_count":19},{"year":2020,"cited_by_count":16},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":11},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":12},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":12},{"year":2012,"cited_by_count":24}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}